Revenue
2021
2022
2023
2024
2025
C4 Therapeutics, Inc. (CCCC)
Price$3.76Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M | — | — |
| Research & development | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M | $78.4M | $48.1M |
| Operating expenses | $151.2M | $155.2M | $159.8M | $160.6M | $127.9M | $93.6M | $56.8M |
| Operating income | −$115.2M | −$119.6M | −$139.0M | −$129.5M | −$82.1M | −$60.4M | −$35.5M |
| Operating margin | −320.53% | −336.15% | −669.84% | −416.56% | −179.39% | — | — |
| EBITDA | −$113.3M | −$117.8M | −$137.2M | −$127.9M | −$80.6M | −$58.8M | −$33.9M |
| EBITDA margin | −315.08% | −331.04% | −660.78% | −411.17% | −176.13% | — | — |
| Net income | −$105.0M | −$105.3M | −$132.5M | −$128.2M | −$83.9M | −$66.3M | −$34.1M |
| Net profit margin | −292.08% | −295.96% | −638.34% | −412.19% | −183.23% | — | — |
| Basic EPSper basic share | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | -$31.03 |
| Diluted EPSper diluted share | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | -$31.03 |
Owners
Reported shareholders
7.21%of listed shares
MORGAN STANLEY8.87M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MORGAN STANLEY | 7.21%8.87M shares |
RA CAPITAL MANAGEMENT, L.P. | 6.51%8M shares |
BlackRock, Inc. | 6.43%7.9M shares |
Lynx1 Capital Management LP | 5.96%7.33M shares |
Squadron Capital Management LLC | 5.86%7.2M shares |
Bain Capital Life Sciences Investors, LLC | 5.84%7.17M shares |
JPMORGAN CHASE & CO | 3.86%4.75M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.59%4.42M shares |
CITADEL ADVISORS LLC | 3.41%4.19M shares |
GOLDMAN SACHS GROUP INC | 2.87%3.53M shares |
WASATCH ADVISORS LP | 2.87%3.52M shares |
TWO SIGMA INVESTMENTS, LP | 2.82%3.47M shares |
Soleus Capital Management, L.P. | 2.75%3.38M shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 2.47%3.03M shares |
BANK OF AMERICA CORP /DE/ | 2.16%2.66M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.05%2.52M shares |
Ikarian Capital, LLC | 1.98%2.43M shares |
STATE STREET CORP | 1.72%2.12M shares |
ACADIAN ASSET MANAGEMENT LLC | 1.47%1.81M shares |
Candriam S.C.A. | 1.46%1.8M shares |
Percentages use 122.91M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 16, 2026Form 4 | REYNO LEONARDChief Medical Officer | SellCommon Stock | 10.0K | $2.22 | $22.2K | 156.4K |
| Feb 18, 2025Form 4 · 10b5-1 | Boyle Scott NChief Business Officer | SellCommon Stock | 669 | $3.15 | $2.1K | 107.8K |
| Feb 14, 2025Form 4 · 10b5-1 | Boyle Scott NChief Business Officer | SellCommon Stock | 490 | $3.15 | $1.5K | 110.8K |
Community posts
C4 advances cemsidomide combination testing alongside new biomarker data
C4 Therapeutics ($CCCC) presented new biomarker findings from its cemsidomide program in multiple myeloma, describing immune activation observed with cemsidomide and dexamethasone. It also reported biomarker results from the first two patie ...
